New drug NTB003 enters first human safety tests
NCT ID NCT07182552
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 trial is testing a new drug called NTB003 in 40 healthy adults to see if it is safe and how the body processes it. Participants will receive either NTB003 or a placebo in increasing doses. The study is an early step toward possibly treating thyroid eye disease, but it does not yet involve patients with the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NTB003
- What this could lead to
- If this early safety study succeeds, it could pave the way for testing NTB003 as a treatment for thyroid eye disease.
- What could go wrong
- This is a very early Phase 1 trial in only 40 healthy people, not patients. It is designed to check safety, not effectiveness, so success here does not guarantee the drug will work for the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aerospace Center Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.